CAS Medical Systems names Dr. John Gamelin
Branford, Conn. (December 17, 2012) CAS Medical Systems, Inc. (“CASMED”) (NASDAQ: CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, announces the promotion of John Gamelin, Ph.D., to Vice President, Research & Development. Dr. Gamelin has been with CASMED since 2009 and most recently served as Director of Research & Development.
“John has made a tremendous contribution to the revitalization of CASMED and is responsible for driving the three major development programs that will deliver new products in each of our core markets within the next year, said Tom Patton, Chief Executive Officer of CASMED. In addition to Johns management skills, as a small company we benefit greatly from his entrepreneurial talents and his broad scientific and clinical competencies. We are pleased to make this well-deserved promotion and elevate John to senior management of the Company.”
Dr. Gamelin has more than 20 years of experience inventing and developing optical, acoustic, and electronic instrumentation, from research concept to commercial production. Prior to joining CASMED, he served as Research Assistant Professor at the University of Connecticut in its Biomedical Engineering program, where he conducted research on novel optical, ultrasound, and radiation imaging modalities for cancer detection and diagnostics. Previously, as a co-founder and Vice President of Engineering for Tellium, an optical switching company, John was a key player in driving that company from start-up to over $100 million in revenues in just four years. At Tellium he ultimately led a development organization of over 200 professionals through major releases of various products, including the largest capacity optical switch available commercially. He began his career as a Senior Scientist at Bellcore, the research and engineering organization for the Regional Bell Operating Companies.
Dr. Gamelin holds four U.S. patents in optical cross-connects and switching technology and several patent applications in biomedical imaging and medical instrumentation. He is the author or co-author of more than 50 publications on topics that include biomedical imaging and laser transmitters. He received his Ph.D. in electrical engineering from the University of California, Berkeley, and his B.S. in electrical engineering from the University of Florida, Gainesville, graduating with distinction as Valedictorian.
About CASMED® - Monitoring What's Vital
CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care.
For further information regarding CASMED, visit the Company's website at www.casmed.com.
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Companys Form 10-K for the year ended December 31, 2011, and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.